Cargando…

Development and Evaluation of a Human Skin Equivalent in a Semiautomatic Microfluidic Diffusion Chamber

There is an increasing demand for transdermal transport measurements to optimize topical drug formulations and to achieve proper penetration profile of cosmetic ingredients. Reflecting ethical concerns the use of both human and animal tissues is becoming more restricted. Therefore, the focus of derm...

Descripción completa

Detalles Bibliográficos
Autores principales: Tárnoki-Zách, Júlia, Mehes, Elod, Varga-Medveczky, Zsófia, Isai, Dona Greta, Barany, Nandor, Bugyik, Edina, Revesz, Zsolt, Paku, Sándor, Erdo, Franciska, Czirok, Andras
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235028/
https://www.ncbi.nlm.nih.gov/pubmed/34202971
http://dx.doi.org/10.3390/pharmaceutics13060910
_version_ 1783714220673597440
author Tárnoki-Zách, Júlia
Mehes, Elod
Varga-Medveczky, Zsófia
Isai, Dona Greta
Barany, Nandor
Bugyik, Edina
Revesz, Zsolt
Paku, Sándor
Erdo, Franciska
Czirok, Andras
author_facet Tárnoki-Zách, Júlia
Mehes, Elod
Varga-Medveczky, Zsófia
Isai, Dona Greta
Barany, Nandor
Bugyik, Edina
Revesz, Zsolt
Paku, Sándor
Erdo, Franciska
Czirok, Andras
author_sort Tárnoki-Zách, Júlia
collection PubMed
description There is an increasing demand for transdermal transport measurements to optimize topical drug formulations and to achieve proper penetration profile of cosmetic ingredients. Reflecting ethical concerns the use of both human and animal tissues is becoming more restricted. Therefore, the focus of dermal research is shifting towards in vitro assays. In the current proof-of-concept study a three-layer skin equivalent using human HaCaT keratinocytes, an electrospun polycaprolactone mesh and a collagen-I gel was compared to human excised skin samples. We measured the permeability of the samples for 2% caffeine cream using a miniaturized dynamic diffusion cell (“skin-on-a-chip” microfluidic device). Caffeine delivery exhibits similar transport kinetics through the artificial skin and the human tissue: after a rapid rise, a long-lasting high concentration steady state develops. This is markedly distinct from the kinetics measured when using cell-free constructs, where a shorter release was observable. These results imply that both the established skin equivalent and the microfluidic diffusion chamber can serve as a suitable base for further development of more complex tissue substitutes.
format Online
Article
Text
id pubmed-8235028
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82350282021-06-27 Development and Evaluation of a Human Skin Equivalent in a Semiautomatic Microfluidic Diffusion Chamber Tárnoki-Zách, Júlia Mehes, Elod Varga-Medveczky, Zsófia Isai, Dona Greta Barany, Nandor Bugyik, Edina Revesz, Zsolt Paku, Sándor Erdo, Franciska Czirok, Andras Pharmaceutics Article There is an increasing demand for transdermal transport measurements to optimize topical drug formulations and to achieve proper penetration profile of cosmetic ingredients. Reflecting ethical concerns the use of both human and animal tissues is becoming more restricted. Therefore, the focus of dermal research is shifting towards in vitro assays. In the current proof-of-concept study a three-layer skin equivalent using human HaCaT keratinocytes, an electrospun polycaprolactone mesh and a collagen-I gel was compared to human excised skin samples. We measured the permeability of the samples for 2% caffeine cream using a miniaturized dynamic diffusion cell (“skin-on-a-chip” microfluidic device). Caffeine delivery exhibits similar transport kinetics through the artificial skin and the human tissue: after a rapid rise, a long-lasting high concentration steady state develops. This is markedly distinct from the kinetics measured when using cell-free constructs, where a shorter release was observable. These results imply that both the established skin equivalent and the microfluidic diffusion chamber can serve as a suitable base for further development of more complex tissue substitutes. MDPI 2021-06-20 /pmc/articles/PMC8235028/ /pubmed/34202971 http://dx.doi.org/10.3390/pharmaceutics13060910 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tárnoki-Zách, Júlia
Mehes, Elod
Varga-Medveczky, Zsófia
Isai, Dona Greta
Barany, Nandor
Bugyik, Edina
Revesz, Zsolt
Paku, Sándor
Erdo, Franciska
Czirok, Andras
Development and Evaluation of a Human Skin Equivalent in a Semiautomatic Microfluidic Diffusion Chamber
title Development and Evaluation of a Human Skin Equivalent in a Semiautomatic Microfluidic Diffusion Chamber
title_full Development and Evaluation of a Human Skin Equivalent in a Semiautomatic Microfluidic Diffusion Chamber
title_fullStr Development and Evaluation of a Human Skin Equivalent in a Semiautomatic Microfluidic Diffusion Chamber
title_full_unstemmed Development and Evaluation of a Human Skin Equivalent in a Semiautomatic Microfluidic Diffusion Chamber
title_short Development and Evaluation of a Human Skin Equivalent in a Semiautomatic Microfluidic Diffusion Chamber
title_sort development and evaluation of a human skin equivalent in a semiautomatic microfluidic diffusion chamber
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235028/
https://www.ncbi.nlm.nih.gov/pubmed/34202971
http://dx.doi.org/10.3390/pharmaceutics13060910
work_keys_str_mv AT tarnokizachjulia developmentandevaluationofahumanskinequivalentinasemiautomaticmicrofluidicdiffusionchamber
AT meheselod developmentandevaluationofahumanskinequivalentinasemiautomaticmicrofluidicdiffusionchamber
AT vargamedveczkyzsofia developmentandevaluationofahumanskinequivalentinasemiautomaticmicrofluidicdiffusionchamber
AT isaidonagreta developmentandevaluationofahumanskinequivalentinasemiautomaticmicrofluidicdiffusionchamber
AT baranynandor developmentandevaluationofahumanskinequivalentinasemiautomaticmicrofluidicdiffusionchamber
AT bugyikedina developmentandevaluationofahumanskinequivalentinasemiautomaticmicrofluidicdiffusionchamber
AT reveszzsolt developmentandevaluationofahumanskinequivalentinasemiautomaticmicrofluidicdiffusionchamber
AT pakusandor developmentandevaluationofahumanskinequivalentinasemiautomaticmicrofluidicdiffusionchamber
AT erdofranciska developmentandevaluationofahumanskinequivalentinasemiautomaticmicrofluidicdiffusionchamber
AT czirokandras developmentandevaluationofahumanskinequivalentinasemiautomaticmicrofluidicdiffusionchamber